scholarly journals Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection

2022 ◽  
Vol 2022 ◽  
pp. 1-3
Author(s):  
Joana Vasconcelos ◽  
João Domingos ◽  
Lia Bastos ◽  
Teresa Baptista ◽  
Kamal Mansinho

Chronic hepatitis B (CHB) is a potentially life-threatening and prevalent disease worldwide. Far from attaining the ultimate treatment goal, hepatitis B virus (HBV) infection eradication, the two current therapeutic options aim to prevent progression to end-stage liver disease, maintaining long-term suppression of HBV replication. Pegylated interferon-α (PEG-INFα) is often poorly tolerated and disregarded considering the orally administered nucleos(t)ide analogues. However, PEG-INFα may achieve similar treatment endpoints with a finite course of treatment. We report a case of PEG-INFα-treated CHB that attained sustained off-treatment virological response with only 16 weeks of treatment, with loss of both HBeAg and HBsAg (this latter the optimal treatment endpoint).

2016 ◽  
Vol 47 (8) ◽  
pp. 747-754 ◽  
Author(s):  
Gian Paolo Caviglia ◽  
Maria Lorena Abate ◽  
Daniele Noviello ◽  
Antonella Olivero ◽  
Chiara Rosso ◽  
...  

1994 ◽  
Vol 39 (9) ◽  
pp. 2014-2021 ◽  
Author(s):  
Jane W. S. Fang ◽  
P. C. WU ◽  
C. L. Lai ◽  
C. K. LO ◽  
Anthony Meager ◽  
...  

Hepatology ◽  
1991 ◽  
Vol 13 (2) ◽  
pp. 332-338 ◽  
Author(s):  
Johnson Y. N. Lau ◽  
Nick Sheron ◽  
Alan G. Morris ◽  
Adrian B. Bomford ◽  
Graeme J. M. Alexander ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document